WKL Wolters Kluwer NV

Wolters Kluwer Appoints Leaders for its Health and Legal & Regulatory Divisions

Wolters Kluwer Appoints Leaders for its Health and Legal & Regulatory Divisions

Wolters Kluwer Appoints Leaders for its Health and Legal & Regulatory Divisions

May 14, 2020 – Wolters Kluwer, a global provider of professional information, software solutions, and services, announces the appointments of Stacey Caywood as CEO of its division and Martin O’Malley as EVP & MD of its division.

Nancy McKinstry, CEO and Chairman of the Executive Board of Wolters Kluwer, commented: “We are very pleased to announce new positions for two of our most talented and experienced leaders. Stacey Caywood’s excellent leadership skills and strong track record of developing information and software portfolios will bring great benefits to the Health division and its global customer base. Martin O’Malley’s demonstrated success in leading businesses through change and in driving product innovation will continue the transformation of the Legal & Regulatory division into an expert solutions business.” 

Stacey Caywood will become the CEO of Health as of June 1, 2020, succeeding Diana Nole who is leaving Wolters Kluwer. As CEO of the Legal & Regulatory division, Ms. Caywood led the transformation of this multi-national business into a growing and innovative provider of digital legal and regulatory solutions by accelerating digital product development, investing in transformative new technologies, and by creating a culture of innovation and customer collaboration. She simultaneously led the division’s strategic expansion into the environmental, health & safety and operational risk (EHS/ORM) adjacency through selected acquisitions, expanding into an attractive and high-growth global software market. 

Martin O’Malley will become the Executive Vice President and Managing Director of the Legal & Regulatory division as of June 1, 2020, succeeding Ms. Caywood. Mr. O’Malley joined Wolters Kluwer in September 2017 and currently serves as the Managing Director for the Benelux region of Legal & Regulatory. Prior to joining Wolters Kluwer in 2017, Mr. O’Malley spent more than 20 years in a variety of roles in the industry, gaining extensive experience in migrating traditional publishing businesses online through digital product development and business model evolution.

Diana Nole will leave Wolters Kluwer to take a position in another company. We thank her for her dedication to our Health division since 2015 and wish her the very best.

Resources for the media:

About Wolters Kluwer

Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the healthcare; tax and accounting; governance, risk and compliance; and legal and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.

Wolters Kluwer reported 2019 annual revenues of €4.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt (ADR) program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).

For more information, visit , follow us on , , , and .

Media                                                                           Investors/Analysts

Gerbert van Genderen Stort                                        Meg Geldens

Media Relations Manager                                            Investor Relations

t                                                         t          

               

Attachment

EN
14/05/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Wolters Kluwer NV

 PRESS RELEASE

Share Buyback Transaction Details December 11 – December 17, 2025

Share Buyback Transaction Details December 11 – December 17, 2025 PRESS RELEASE                                         Share Buyback Transaction Details December 11 – December 17, 2025 Alphen aan den Rijn – December 18, 2025 - Wolters Kluwer (Euronext: WKL), a global leader in professional information solutions, software and services, today reports that it has repurchased 238,453 of its own ordinary shares in the period from December 11, 2025, up to and including December 17, 2025, for €21.4 million and at an average share price of €89.85. These repurchases are part of the share buyback...

 PRESS RELEASE

Share Buyback Transaction Details December 4 – December 10, 2025

Share Buyback Transaction Details December 4 – December 10, 2025 PRESS RELEASE                                         Share Buyback Transaction Details December 4 – December 10, 2025 Alphen aan den Rijn – December 11, 2025 - Wolters Kluwer (Euronext: WKL), a global leader in professional information solutions, software and services, today reports that it has repurchased 209,603 of its own ordinary shares in the period from December 4, 2025, up to and including December 10, 2025, for €18.7 million and at an average share price of €89.33. These repurchases are part of the share buyback pr...

David Vagman ... (+5)
  • David Vagman
  • CFA
  • Marc Hesselink
  • CFA
  • Thymen Rundberg

Wolters Kluwer/AI winner at an attractive valuation/BUY

Our conviction in the Wolters Kluwer investment case remains high. Three positives stand out in our view. Firstly, current trading is solid, with 9M25 organic revenue growth beating expectations. Secondly, the company's expert curated (proprietary) content is a strong moat vs AI-only alternatives as the company operates in high-stake environments where reliability is key. Thirdly, valuation has become highly attractive. We slightly lower our target price to €160 per share (from €173). We keep ou...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch